Adial Pharmaceuticals, Inc.
NASDAQ: ADIL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Cary John Claiborne
- Employees
- 5
- Headquarters
- Charlottesville, United States
- IPO year
- 2018
- Market cap
- $2.4M
- Website
- https://www.adialpharma.com
Loading ADIL…
Loading profile data…Frequently asked questions about ADIL
What does Adial Pharmaceuticals, Inc. (ADIL) do?
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently...
Where does ADIL trade?
Adial Pharmaceuticals, Inc. (ADIL) trades on the NASDAQ Capital Market.
What sector is ADIL in?
Adial Pharmaceuticals, Inc. (ADIL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Adial Pharmaceuticals, Inc.?
Cary John Claiborne is the chief executive officer of Adial Pharmaceuticals, Inc. (ADIL).
Where is Adial Pharmaceuticals, Inc. headquartered?
Adial Pharmaceuticals, Inc. is headquartered in United States.
Does ADIL pay a dividend?
Adial Pharmaceuticals, Inc. (ADIL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ADIL go public?
Adial Pharmaceuticals, Inc. (ADIL) completed its initial public offering in 2018.